Effectiveness of Topical Amorolfine, Luliconazole, Sertaconazole, and Terbinafine in the Management of Tinea Corporis and Cruris: A Comparative Analysis
Aim: To evaluate and compare the therapeutic effectiveness of topical amorolfine, luliconazole, sertaconazole, and terbinafine in the treatment of tinea corporis and tinea cruris. Materials and Methods: This was a prospective, randomized, open-label, parallel-group study conducted in the Department of Dermatology. Designed as a pragmatic trial, the study aimed to assess the clinical response to commonly used topical antifungal agents in the current dermatophytosis scenario. Clinically diagnosed, immunocompetent adult patients (≥18 years) with localized tinea corporis or tinea cruris, and no history of antifungal therapy in the preceding week, were enrolled.A total of 80 patients were included, with 20 patients allocated to each treatment arm. Eligible participants were assigned to receive one of the following topical agents in a sequential manner: amorolfine 0.25%, luliconazole 1%, sertaconazole 2%, or terbinafine 1%. The same brand of each drug was used consistently throughout the study. Amorolfine and luliconazole were applied once daily, whereas sertaconazole and terbinafine were applied twice daily. Results: The mean age of participants was 34 years (range: 18–70 years), with a male-to-female ratio of 1.1:1 (35 males, 32 females). Thirteen participants were lost to follow-up despite telephonic reminders. Luliconazole demonstrated the greatest improvement in pruritus (mean: 1.47), erythema (mean: 1.53), and scaling (mean: 1.53). In contrast, terbinafine showed the least improvement, with mean values of 0.73 (pruritus), 0.60 (erythema), and 0.67 (scaling). The difference in mean improvement scores for luliconazole was statistically significant for pruritus (P = 0.020) and highly significant for erythema and scaling (P = 0.004 and 0.007, respectively). Based on cumulative improvement in all three parameters, patients were categorized as follows: poor response (score 0–2), moderate response (score 3–4), and good response (score 5–6). In the luliconazole group, 12 patients (66%) demonstrated a good response, which was statistically significant compared to the other groups (P = 0.018, Fisher’s exact test). Conclusion: Luliconazole appears to be more effective than amorolfine, sertaconazole, and terbinafine in the treatment of tinea corporis and cruris. Although classified under the azole group, luliconazole may exhibit fungicidal activity. Further studies involving larger sample sizes are warranted to confirm these findings.